| Dr Thomas T Dovan, MD | |
|
2004 Hayes St Ste 200, Nashville, TN 37203-2689 | |
| (615) 324-1600 | |
| (615) 324-1661 |
| Full Name | Dr Thomas T Dovan |
|---|---|
| Gender | Male |
| Speciality | Hand Surgery |
| Experience | 27 Years |
| Location | 2004 Hayes St Ste 200, Nashville, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063525665 | NPI | - | NPPES |
| 863047310A | Medicaid | GA |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Elite Sports Medicine And Orthopaedic Center Plc | 8729009634 | 69 |
| Select Physical Therapy Holdings Inc | 9537076401 | 1487 |
News Archive
Researchers at the Translational Genomics Research Institute (TGen) may have found a way to stop the often-rapid spread of deadly brain tumors.
Patient Safety Technologies, Inc. today announced financial results for its first quarter of 2011 ended March 31, 2011.
Researchers identified 14 new markers that could identify in early pregnancy who may be at risk of developing preeclampsia in later pregnancy. An international team of scientists and physicians used a combination of sophisticated emerging technologies and data analysis to detect 14 simple metabolites with high accuracy to predict in early pregnancy which women are at risk of developing preeclampsia in later pregnancy.
Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today first dosing of subjects in a Phase 1 clinical trial of TCN-202, a broadly protective, fully human monoclonal antibody in development for the treatment of human cytomegalovirus (CMV) infection.
› Verified 4 days ago
| Entity Name | Elite Sports Medicine And Orthopaedic Center Plc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528281623 PECOS PAC ID: 8729009634 Enrollment ID: O20051207000566 |
News Archive
Researchers at the Translational Genomics Research Institute (TGen) may have found a way to stop the often-rapid spread of deadly brain tumors.
Patient Safety Technologies, Inc. today announced financial results for its first quarter of 2011 ended March 31, 2011.
Researchers identified 14 new markers that could identify in early pregnancy who may be at risk of developing preeclampsia in later pregnancy. An international team of scientists and physicians used a combination of sophisticated emerging technologies and data analysis to detect 14 simple metabolites with high accuracy to predict in early pregnancy which women are at risk of developing preeclampsia in later pregnancy.
Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today first dosing of subjects in a Phase 1 clinical trial of TCN-202, a broadly protective, fully human monoclonal antibody in development for the treatment of human cytomegalovirus (CMV) infection.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Thomas T Dovan, MD 2021 Church St., Suite 200, Nashville, TN 37203 Ph: (615) 284-2000 | Dr Thomas T Dovan, MD 2004 Hayes St Ste 200, Nashville, TN 37203-2689 Ph: (615) 324-1600 |
News Archive
Researchers at the Translational Genomics Research Institute (TGen) may have found a way to stop the often-rapid spread of deadly brain tumors.
Patient Safety Technologies, Inc. today announced financial results for its first quarter of 2011 ended March 31, 2011.
Researchers identified 14 new markers that could identify in early pregnancy who may be at risk of developing preeclampsia in later pregnancy. An international team of scientists and physicians used a combination of sophisticated emerging technologies and data analysis to detect 14 simple metabolites with high accuracy to predict in early pregnancy which women are at risk of developing preeclampsia in later pregnancy.
Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today first dosing of subjects in a Phase 1 clinical trial of TCN-202, a broadly protective, fully human monoclonal antibody in development for the treatment of human cytomegalovirus (CMV) infection.
› Verified 4 days ago
Dr. Robert Joel Otto, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2400 Patterson St Ste 100, Nashville, TN 37203 Phone: 615-342-0038 | |
James Hardman Rubright, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 345 23rd Ave N, Suite 212, Nashville, TN 37203 Phone: 615-963-9200 Fax: 615-963-9201 | |
Alexander David Savage, Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 2400 Patterson St Ste 100, Nashville, TN 37203 Phone: 615-342-0038 | |
William Edward Carpenter, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 8 City Blvd Ste 300, Nashville, TN 37209 Phone: 615-823-8891 Fax: 615-321-6226 | |
Daniel Nuri Kiridly, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3443 Dickerson Pike Ste 190, Nashville, TN 37207 Phone: 615-860-1580 | |
Dr. Chelsea Brown, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 3601 The Vanderbilt Clinic, Nashville, TN 37232 Phone: 615-322-5000 | |
Dr. Jane Merideth Siegel, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 301 21st Ave N, Nashville, TN 37203 Phone: 615-329-6600 Fax: 615-695-1483 |